精准医学诊所:分子肿瘤委员会
Precision Medicine Clinic: Molecular Tumor Board


精准医学诊所:分子肿瘤委员会通过一系列以病例为基础的研讨,帮助医师优化患者的分子诊断。《肿瘤学家》杂志鼓励相关研究机构分享发现和经验来帮助提高基因肿瘤学的精准度,改善患者结局。本合集精选了不同患者,展示了一系列肿瘤类型和突变情形,希望能够给您的临床实践带来相关获益

Precision Medicine Clinic: Molecular Tumor Board is a case-based series designed to help clinicians optimize molecular testing for their patients. The Editors of The Oncologist encourage institutions to share their findings and experiences to help improve the precision of genomic oncology and fulfill its promise of improved outcomes for patients. This collection highlights a diverse set of patients exhibiting a range of tumor types and mutations. We hope you find the clinical outcomes beneficial in your practice.


Understanding the Precision in “Precision Medicine”
Bruce A. Chabner
The Oncologist 2016; 21:1029-1030; first published on August 26, 2016;doi:10.1634/theoncologist.2016-0278
http://theoncologist.alphamedpress.org/content/21/9/1029

ESR1突变的转移性乳腺癌:麻省总医院分子与精准医疗(MAP)肿瘤委员会的临床管理思考
Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital

Aditya Bardia, John A. Iafrate, Tilak Sundaresan, Jerry Younger, Valentina Nardi
The Oncologist 2016; 21:1035-1040; first published on August 22, 2016; doi:10.1634/theoncologist.2016-0240
http://theoncologist.alphamedpress.org/content/21/9/1035.abstract.zh

Detection of anALK Fusion in Colorectal Carcinoma by Hybrid Capture‐Based Assay of Circulating Tumor DNA
Andrea Z. Lai, Alexa B. Schrock, Rachel L. Erlich, Jeffrey S. Ross, Vincent A. Miller, Evgeny Yakirevich, Siraj M. Ali, Fadi Braiteh
The Oncologist 2017; 22:774-779; first published on May 15, 2017; doi:10.1634/theoncologist.2016-0376
http://theoncologist.alphamedpress.org/content/22/7/774

A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases
Victoria E. Wang, Lauren Young, Siraj Ali, Vincent A. Miller, Anatoly Urisman, John Wolfe, Trever G. Bivona, Bertil Damato, Shannon Fogh, Emily K. Bergsland
The Oncologist 2017; 22:768-773; first published on May 15, 2017; doi:10.1634/theoncologist.2017-0054
http://theoncologist.alphamedpress.org/content/22/7/768

Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center
Andrew Sharabi, Sangwoo Shawn Kim, Shumei Kato, Philip D. Sanders, Sandip Pravin Patel, Parag Sanghvi, Elizabeth Weihe, Razelle Kurzrock
The Oncologist 2017; 22:631-637; first published on May 26, 2017; doi:10.1634/theoncologist.2016-0517
http://theoncologist.alphamedpress.org/content/22/6/631

DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity
Enrico Castellucci, Tianfang He, D. Yitzchak Goldstein, Balazs Halmos, Jennifer Chuy
The Oncologist 2017; 22:497-502; first published on May 2, 2017; doi:10.1634/theoncologist.2017-0034oi:10.1634/theoncologist.2016-0517
http://theoncologist.alphamedpress.org/content/22/5/497

Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer
Revathi Kollipara, Bryan Schneider, Milan Radovich, Sunil Babu, Patrick J. Kiel
The Oncologist 2017; 22:1149-1151; first published on August 4, 2017; doi:10.1634/theoncologist.2017-0096
http://theoncologist.alphamedpress.org/content/22/10/1149.abstract

Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E
Hiromasa Yamamoto, Shinichi Toyooka, Takashi Ninomiya, Shigemi Matsumoto, Masashi Kanai, Shuta Tomida, Katsuyuki Kiura, Manabu Muto, Ken Suzawa, Patrice Desmeules, Mark G. Kris, Bob T. Li, Marc Ladanyi
The Oncologist 2018; 23:150-154; first published on November 16, 2017; doi:10.1634/theoncologist.2017-0345
http://theoncologist.alphamedpress.org/content/23/2/150.abstract.zh

Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE‐Mutant Uterine Carcinosarcoma
Munveer S. Bhangoo, Peter Boasberg, Pareen Mehta, Julia A. Elvin, Siraj M. Ali, Winnie Wu, Samuel J. Klempner
The Oncologist first published on January 31, 2018; doi:10.1634/theoncologist.2017-0342
http://theoncologist.alphamedpress.org/content/early/2018/01/31/theoncologist.2017-0342.abstract

The Perils of Single‐Site Genetic Testing for Hereditary Cancer Syndromes in the Era of Next‐Generation Sequencing
Nicole Casasanta, Elizabeth Stark, Allison McHenry, Tara Biagi, Rebecca Kaltman
The Oncologist first published on February 14, 2018; doi:10.1634/theoncologist.2017-0372
http://theoncologist.alphamedpress.org/content/early/2018/02/14/theoncologist.2017-0372.abstract

Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair‐Deficient Endometrial Cancer and a Germline BRCA1 Mutation
Don S. Dizon, Dora Dias‐Santagata, Amy Bregar, Laura Sullivan, Jennifer Filipi, Elizabeth DiTavi, Lucy Miller, Leif Ellisen, Michael Birrer, Marcela DelCarmen
The Oncologist first published on February 22, 2018; doi:10.1634/theoncologist.2017-0526
http://theoncologist.alphamedpress.org/content/early/2018/02/22/theoncologist.2017-0526.abstract